GI
HAE icon

GAMMA Investing’s Haemonetics HAE Stock Holding History

GAMMA Investing’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$94.1K Buy
894
+91
+11% +$8.47K ﹤0.01% 1916
2026
Q2 		$60.2K Buy
803
+459
+133% +$29.5K ﹤0.01% 2176
2026
Q1 		$19.4K Buy
344
+90
+35% +$5.86K ﹤0.01% 2727
2025
Q4 		$20.4K Buy
254
+130
+105% +$8.73K ﹤0.01% 2608
2025
Q3 		$6.04K Sell
124
-319
-72% -$19.7K ﹤0.01% 3096
2025
Q2 		$33.1K Buy
443
+165
+59% +$10.9K ﹤0.01% 2181
2025
Q1 		$17.7K Buy
278
+122
+78% +$8.3K ﹤0.01% 2462
2024
Q4 		$12.2K Buy
156
+62
+66% +$4.98K ﹤0.01% 2508
2024
Q3 		$7.56K Sell
94
-43
-31% -$3.47K ﹤0.01% 2568
2024
Q2 		$11.3K Buy
137
+109
+389% +$9.59K ﹤0.01% 2181
2024
Q1 		$2.39K Sell
28
-31
-53% -$2.43K ﹤0.01% 2698
2023
Q4 		$4.51K Buy
+59
New +$5.1K ﹤0.01% 2287

Other funds holding HAE

CIM
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing's HAE Position: Q3 2026 in Review

GAMMA Investing increased its Haemonetics (HAE) stake by 11% in Q3 2026, buying an estimated $8.47K and bringing the position to 894 shares worth $94.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

GAMMA Investing first reported a position in HAE in Q4 2023 and has held it in 12 quarters since. 7 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • GAMMA Investing held 894 shares of Haemonetics worth $94.1K as of Q3 2026.
  • GAMMA Investing bought 91 Haemonetics shares in Q3 2026, an estimated $8.47K.
  • Haemonetics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #1916 holding.
  • GAMMA Investing first reported a position in Haemonetics in Q4 2023 and has held it in 12 quarters since.
  • 7 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.